UPDATED: Be the spark? Roche’s Spark sues fellow gene therapy developer bluebird for ‘usurpation’ of trademark
Spark Therapeutics takes a lot of pride in the brand it’s built up over the last eight years. And it wants bluebird bio to know that.
The Philadelphia-based gene therapy player, which is now a subsidiary of Roche, has sued bluebird for trademark infringement — through a promotional campaign around its experimental treatment for sickle cell disease where the word “spark” features prominently. According to Spark, that amounts to “usurpation.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,900+ biopharma pros reading Endpoints daily — and it's free.